ARTBIO is a clinical-stage radiopharmaceutical biotechnology company focused on developing a new class of alpha radioligand therapies (ART). Our unique patient-centric approach is underpinned by a deep understanding of cancer biology and the infrastructure needed to effectively design, manufacture, and distribute our therapies.

Biotechnology

ARTBIO

Emanuele Ostuni

Calvin J. Lee

Jordi Vall-Llossera

Daniel Rossetto

Alex Pasteur

Victor Paulus

Jordi Vall - Llosera Ferran

Philippe Dasse

Nick Pullen

Leadership Team

Product Development and Quality Assurance

Teams at ARTBIO

Leadership Team

Product Development and Quality Assurance